The NY Times has a balanced, in-depth article on the benefits and drawbacks of Merck’s and GlaxoSmithKline’s efforts on the cervical cancer front. They recount the marketing efforts behind the vaccine as well as the questions surrounding the cost / benefit analysis that exists.
Categories